Skip to content
OpenCapital
Get started

Achieve Life Sciences ACHV Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Sionna Therapeutics, Inc. Common Stock logo
Sionna Therapeutics, Inc. Common StockSION
$64.29M-23.2%
Philip Morris International logo
Philip Morris InternationalPM
$5.47B+22.2%

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0—
Free cash flow-$12.4M—

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Debt / equity0.5×+0.4×
Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's cash & equivalents?
Achieve Life Sciences (ACHV) reported cash & equivalents of $28.08M in Q1 2026.
How has Achieve Life Sciences's cash & equivalents changed year-over-year?
Achieve Life Sciences's cash & equivalents increased by 115.7% year-over-year, from $13.02M to $28.08M.
What is the long-term trend for Achieve Life Sciences's cash & equivalents?
Over 5 years (2020 to 2025), Achieve Life Sciences's cash & equivalents has grown at a -10.2% compound annual growth rate (CAGR), from $35.85M to $20.93M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.